Ginkgo bioworks acquires reverie labs platform, enhancing ai-driven drug discovery capabilities for customer programs

Boston , feb. 28, 2024 /prnewswire/ -- today, ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, announced the acquisition of key assets of reverie labs, which built and used ai/ml tools to accelerate drug discovery. ginkgo has acquired reverie's infrastructure and software for training large-scale ai foundation models and four of reverie's key ai team members will join ginkgo.
DNA Ratings Summary
DNA Quant Ranking